BioSpace News Archive

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced the first patients have been dosed in its global Phase 1 clinical trial of ADG126 for the treatment of various advanced solid tumors.

Ipsen Biopharmaceuticals Canada Inc. today announced the commercial availability of INCRELEX® (mecasermin) for the treatment of growth failure in children and adolescents from 2 to 18 years with confirmed severe primary insulin-like growth factor-1 deficiency (SPIGFD), following its Health Canada approval in December 2020.

Citrine Medicine , a China -based rare disease therapeutics company, today announced that it will participate in three industry conferences in March, including a presentation at the 2021 WuXi Healthcare Forum, which will be held from March 15-18, 2021 .

COTA, Inc., an oncology real-world data and analytics company, today announced a collaboration with Kite, a Gilead company, through which COTA’s real-world data will be used to accelerate Kite’s drug development pipeline.

EUROIMMUN, a PerkinElmer, Inc. company, today announced the launch of the EUROPatternTM Microscope Live (EPML) compact immunofluorescence microscope, available with the fourth generation of the Company’s well-established EUROLabOfficeTM 4.0 (ELO 4.0) laboratory management software

CRH Medical Corporation, announced financial and operating results for the year and three months ended December 31, 2020.

Elixir Medical , a developer of innovative, drug-eluting cardiovascular devices, today announced commencement of the INFINITY-SWEDEHEART randomized controlled trial (RCT) of the DynamX™ Coronary Bioadaptor System

Havn Life Sciences Inc., a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that industry veteran Jenna Pozar is joining the team as Chief Operating Officer.

NephroSant, a kidney health spin out of UC San Francisco, today announced it has closed its oversubscribed Series A funding round of $16 million. DaVita Venture Group led the investment round, with participation from DigitalDx Ventures and other previous investors.

Diverse Biotech, Inc. www.diversebiotech.com announced today that it has finalized a strategic transaction with Enveric Biosciences to license exclusive worldwide development and commercialization rights for five novel compounds to address the adverse side effects of cancer treatments.